• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Infect Drug Resist . Changes in Clinical Features and Severity of COVID-19 with the Emergence of Omicron Variants: A Shift Towards a Common Disease

tetano

Editor, Senior Moderator
Infect Drug Resist


. 2024 Dec 18:17:5595-5603.
doi: 10.2147/IDR.S492816. eCollection 2024. Changes in Clinical Features and Severity of COVID-19 with the Emergence of Omicron Variants: A Shift Towards a Common Disease

Saori Kawamura[SUP] #[/SUP][SUP] 1 [/SUP], Fumihiro Yamaguchi[SUP] #[/SUP][SUP] 1 [/SUP], Rui Kusakado[SUP] 1 [/SUP], Yoshihiro Go[SUP] 1 [/SUP], Shiho Nohmi[SUP] 1 [/SUP], Chinatsu Yoshizaki[SUP] 1 [/SUP], Yuki Yoshida[SUP] 1 [/SUP], Kensuke Izumizaki[SUP] 1 [/SUP], Yuichiro Saito[SUP] 1 [/SUP], Hitoshi Kobayashi[SUP] 1 [/SUP], Kento Hirata[SUP] 1 [/SUP], Kenta Miyo[SUP] 1 [/SUP], Chika Kondo[SUP] 1 [/SUP], Mamiko Kanzaki[SUP] 1 [/SUP], Yize Ding[SUP] 1 [/SUP], Takuya Yokoe[SUP] 1 [/SUP], Sei Kobayashi[SUP] 2 [/SUP], Hiroshi Suzuki[SUP] 3 [/SUP]



Affiliations
Abstract

Background: The emergence of the Omicron variant of severe acute respiratory syndrome coronavirus-2 has significantly altered the clinical features and severity of coronavirus disease 2019 (COVID-19).
Objective: This study aims to evaluate whether the clinical factors that previously predicted COVID-19 remain valid following the emergence of the Omicron variant.
Methods: This cross-sectional study was conducted at Showa University Fujigaoka Hospital from April 2022 to March 2023. A total of 576 patients with suspected COVID-19 were included, of which 258 (44.8%) were diagnosed with COVID-19 based on real-time reverse-transcription polymerase chain reaction tests. Clinical data were collected retrospectively, and multivariate logistic regression was used to analyze factors associated with a COVID-19 diagnosis.
Results: Of the 258 patients diagnosed with COVID-19, 60% had mild disease, and the overall severity was lower than in previous reports prior to the emergence of the Omicron variant. In the multivariate analysis, only C-reactive protein (CRP) levels were significantly associated with COVID-19 (odds ratio, 0.3164; 95% confidence interval, 0.2077-0.4819), while factors such as age, sex, body mass index, lactate dehydrogenase, and comorbidities were not significantly associated. Non-COVID-19 cases were primarily bacterial infections, accounting for 57.2% of the non-COVID-19 diagnoses. Mortality rates did not differ significantly between the COVID-19 and non-COVID-19 groups.
Conclusion: The clinical characteristics of COVID-19 have become less distinct since the emergence of the Omicron variant, with CRP being the primary marker associated with a COVID-19 diagnosis. As COVID-19 continues to transition towards a more common infectious disease, distinguishing it will become increasingly challenging.

Keywords: C-reactive protein; Omicron variants; coronavirus disease 2019; severe acute respiratory syndrome coronavirus-2.

 
Back
Top Bottom